Clinical Edge Journal Scan

Low Stress Resilience in Adolescence Raises Risk for Psoriatic Arthritis


 

Key clinical point: Low stress resilience during adolescence increased the risk of developing psoriatic arthritis (PsA) later in life in a cohort of >1.6 million men who were followed up for up to 51 years.

Major finding: Over nearly 51 years of follow-up, 9433 (0.6%) men developed first onset PsA. Low vs high stress resilience increased the risk for new-onset PsA by 23% in the overall cohort (adjusted hazard ratio [aHR] 1.23; 95% CI 1.15-1.32) and 53% in the subgroup of patients who were hospitalized due to severe PsA (aHR 1.53; 95% CI 1.32-1.77).

Study details: This prospective cohort study included 1,669,422 men from the Swedish Military Service Conscription Register, of whom 20.4%, 58.0%, and 21.5% had low, medium, and high stress resilience levels, respectively .

Disclosures: This study was supported by the Swedish Research Council for Health and other sources. One author declared receiving honoraria as consultant or speaker from various sources. Other authors declared no conflicts of interest.

Source: Laskowski M, Schiöler L, Åberg M, et al. Influence of stress resilience in adolescence on long-term risk of psoriasis and psoriatic arthritis among men: A prospective register-based cohort study in Sweden. J Eur Acad Dermatol Venereol. 2024 (May 20). doi: 10.1111/jdv.20069 Source

Recommended Reading

Ultrasound Assessment of Clinically Healthy Nails Can Aid in PsA Diagnosis
MDedge Rheumatology
Hematological Indices Plus Ultrasound Can Detect Entheses in Patients With Psoriatic Arthritis
MDedge Rheumatology
Specialists Are ‘Underwater’ With Some Insurance-Preferred Biosimilars
MDedge Rheumatology
Recent Evidence for Home Phototherapy Benefits May Improve Access for Patients with Psoriasis
MDedge Rheumatology
Cortisol Test Confirms HPA Axis Recovery from Steroid Use
MDedge Rheumatology
Commentary: Transition from Psoriasis to PsA and New Drug Analyses, June 2024
MDedge Rheumatology
Study Finds Mace Risk Remains High in Patients with Psoriasis, Dyslipidemia
MDedge Rheumatology
Over-the-Counter Arthritis Supplements Pose Adrenal Danger
MDedge Rheumatology
Clear Coverage Preference for Humira Over Biosimilars Seen in Most Medicare Part D Plans
MDedge Rheumatology
EULAR 2024 Preview: Therapeutics in Development Take Center Stage
MDedge Rheumatology